» Articles » PMID: 15231656

DNA Hypomethylation and Ovarian Cancer Biology

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Jul 3
PMID 15231656
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Hypomethylation of some portions of the genome and hypermethylation of others are very frequent in human cancer. The hypomethylation often involves satellite 2 (Sat2) DNA in the juxtacentromeric (centromere-adjacent) region of chromosome 1. In this study, we analyzed methylation in centromeric and juxtacentromeric satellite DNA in 115 ovarian cancers, 26 non-neoplastic ovarian specimens, and various normal somatic tissue standards. We found that hypomethylation of both types of satellite DNA in ovarian samples increased significantly from non-neoplastic toward cancer tissue. Furthermore, strong hypomethylation was significantly more prevalent in tumors of advanced stage or high grade. Importantly, extensive hypomethylation of Sat2 DNA in chromosome 1 was a highly significant marker of poor prognosis (relative risk for relapse, 4.1, and death, 9.4) and more informative than tumor grade or stage. Also, comparing methylation of satellite DNA and 15 5' gene regions, which are often hypermethylated in cancer or implicated in ovarian carcinogenesis, we generally found no positive or negative association between methylation changes in satellite DNA and in the gene regions. However, hypermethylation at two loci, CDH13 (at 16q24) and RNR1 (at 13p12), was correlated strongly with lower levels of Sat2 hypomethylation. The CDH13/Sat2 epigenetic correlation was seen also in breast cancers. We conclude that satellite DNA hypomethylation is an important issue in ovarian carcinogenesis as demonstrated by: (a) an increase from non-neoplastic tissue toward ovarian cancer; (b) an increase within the ovarian cancer group toward advanced grade and stage; and (c) the finding that strong hypomethylation was an independent marker of poor prognosis.

Citing Articles

CpG hypomethylation at proximal promoter and 5'UTR along with IL6 signaling loop associates with MYD88 upregulation in epithelial ovarian cancer.

Li J, Mei B, Zhu Y, Huang J, Li M, Wang D Sci Rep. 2024; 14(1):30945.

PMID: 39730678 PMC: 11681154. DOI: 10.1038/s41598-024-81975-x.


Methylation changes and INS-IGF2 expression predict progression in early-stage Wilms tumor.

Jalal D, Ali M, Elkinaai N, Abdelaziz A, Zekri W, A Sayed A Clin Epigenetics. 2024; 16(1):170.

PMID: 39593106 PMC: 11590261. DOI: 10.1186/s13148-024-01775-y.


Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach.

Jia W, Li N, Wang J, Gong X, Ouedraogo S, Wang Y EPMA J. 2024; 15(2):375-404.

PMID: 38841623 PMC: 11148001. DOI: 10.1007/s13167-024-00359-3.


Exosomes in diagnostic and therapeutic applications of ovarian cancer.

Bhavsar D, Raguraman R, Kim D, Ren X, Munshi A, Moore K J Ovarian Res. 2024; 17(1):113.

PMID: 38796525 PMC: 11127348. DOI: 10.1186/s13048-024-01417-0.


A Novel Non-Psychoactive Fatty Acid from a Marine Snail, , Signals Cannabinoid Receptor 1 (CB1) to Accumulate Apoptotic C16:0 and C18:0 Ceramides in Teratocarcinoma Cell Line PA1.

Vijayaraghavan C, Raman L, Surenderan S, Kaur H, Chinambedu M, Thyagarajan S Molecules. 2024; 29(8).

PMID: 38675558 PMC: 11052367. DOI: 10.3390/molecules29081737.